文献速递类风湿关节炎其他结缔组织病

系统性风湿病患者COVID-19疫苗接种早期经验:全球风湿病联盟疫苗调查

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
PubMed 文献 · RMD Open · 2021-01-01

该国际在线调查于2021年4月2日至30日纳入2860例已接种COVID-19疫苗的系统性风湿病成人患者,收集临床沟通、DMARD停药意愿及不良事件数据;患者报告不良事件与一般人群类似,需调整药物的疾病 flare 率为4.6%。

要点

  • 81.9%患者与临床医生沟通了疫苗接种,66.9%愿意为增强疫苗效果暂时停用DMARD。
  • 接种后最常见不良事件为疲劳/嗜睡33.4%、头痛27.7%、肌肉/关节痛22.8%、发热/寒战19.9%。
  • 需调整药物的风湿病 flare 发生率为4.6%。

核心结论

  • 系统性风湿病成人接种COVID-19疫苗后患者报告不良事件与一般人群类似,需用药调整的风湿病 flare 频率较低。

研究设计与样本

  • 2021年4月2日至30日开展的国际在线调查,分析2860例已接种COVID-19疫苗的系统性风湿病成人患者自报数据。

主要发现

  • 接种疫苗类型包括Pfizer-BioNTech 53.2%、Oxford/AstraZeneca 22.6%、Moderna 21.3%、Janssen/Johnson & Johnson 1.7%及其他1.2%。
  • 最常见风湿病为类风湿关节炎42.3%,81.2%受访者正在使用DMARD。
  • 81.9%报告与临床医生沟通疫苗接种,66.9%愿意暂时停用DMARD以提高疫苗效力,44.3%担心风湿病 flare。
  • 接种后患者报告不良事件:疲劳/嗜睡33.4%、头痛27.7%、肌肉/关节痛22.8%、发热/寒战19.9%。
  • 需调整药物的风湿病 flare 发生率为4.6%。

临床怎么用

  • 临床医生应与系统性风湿病患者沟通疫苗接种事宜,并个体化讨论围接种期DMARD暂时停用的获益与 flare 风险。

局限性

  • 原文未报告调查抽样方法、应答率及患者报告数据的验证情况等局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine. METHODS: From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination. RESULTS: We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%. CONCLUSION: Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sattui SE, Liew JW, Kennedy K, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021. PMID: 34493645. doi:10.1136/rmdopen-2021-001814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。